Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ for the treatment of people with lupus nephritis a serious complication of systemic lupus erythematosus resulting in ...
Source: investingnews.com